Integration of signal transduction inhibitors with endocrine therapy: An approach to overcoming hormone resistance in breast cancer

Clinical Cancer Research

Volumn 9, Issue 1 II, 2003, Pages

  Johnston, Stephen R D ^a   Head, Julia ^a   Pancholi, Sunil ^a   Detre, Simone ^a   Martin, Lesley Ann ^a   Smith, Ian E ^a   Dowsett, Mitch ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CANERTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; ESTROGEN; ESTROGEN RECEPTOR; GEFITINIB; LAPATINIB; LETROZOLE; LONAFARNIB; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PELITINIB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; SIGNAL TRANSDUCTION INHIBITOR; STRESS ACTIVATED PROTEIN KINASE; TAMOXIFEN; TEMSIROLIMUS; TIPIFARNIB; UNCLASSIFIED DRUG;

BONE MARROW SUPPRESSION; BREAST CANCER; CANCER HORMONE THERAPY; CELL GROWTH; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; ENZYME ACTIVATION; FEMALE; GASTROINTESTINAL SYMPTOM; HORMONE RESISTANCE; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; MOLECULAR INTERACTION; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RASH; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; RECEPTOR CROSS-TALK; SIGNAL TRANSDUCTION;

EID: 0037241504     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (64)

1. Early Breast Cancer Trialist's Group. Tamoxifen for early breast cancer; an overview of the randomised trials. Lancet, 351: 1451-1467, 1998.
2. Jensen, E. V., DeSombre, E. R., and Jungblut, P. W. Estrogen receptors in hormone responsive tissues and tumors. In: R. W. Wissler, T. L. Dao, and S. Wood (eds.), Endogenous Factors Influencing Host-Tumor Balance, pp. 15-30. Chicago: University of Chicago Press, 1967.
3. Johnston, S. R. D., Anderson, E., Dowsett, M., and Howell, A. Hormonal resistance in breast cancer. In: M. Oettel and E. Schillinger (eds.), Handbook of Experimental Pharmacology: Estrogens and Antiestrogens II, pp. 205-221. Berlin: Springer-Verlag, 1999.
4. Johnston, S. R. D., Lu, B., Dowsett, M., Liang, X., Kaufmann, M., Scott, G. K., and Benz, C. C. Comparison of estrogen receptor DNA-binding in untreated and acquired antiestrogen-resistant human breast tumors. Cancer Res., 57: 3723-3727, 1997.
5. Mahfoudi, A., Roulet, E., Dauvois, S., Parker, M. G., and Wahli, W. Specific mutations in the estrogen receptor change the properties of antiestrogens to full agonists. Proc. Natl. Acad. Sci. USA, 92: 4206-4210, 1995.
6. Karnick, P. S., Kulkarni, S., Liu, X-P., Budd, G. T., and Bukowski, R. M. Estrogen receptor mutations in tamoxifen-resistant breast cancer. Cancer Res., 54: 349-353, 1994.
7. Fuqua, S. A. W., Wiltschke, C., Zhang, Q. X., Borg, A., Castles, C. G., Friedrichs, W. E., Hopp, T., Hilsenbeck, S., Mohsin, S., O'Connell, P., and Allred, D. C. A Hypersensitive estrogen receptor-α mutation in premalignant breast lesions. Cancer Res., 60: 4026-4029, 2000.
8. Webb, P., Lopez, G. N., Uht, R. M., and Kushner, P. J. Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol. Endocrinol., 9: 443-456, 1995.
9. Schiff, R., Reddy, P., Ahotupa, M., Coronado-Heinsohn, E., Grim, M., Hilsenbeck, S. G., Lawrence, R., Deneke, S., Herrera, R., Chamness, G. C., Fuqua, S. A. W., Brown, P. H., and Osborne, C. K. Oxidative stress and AP-1. Activity in tamoxifen-resistant breast tumors in vivo. J. Natl. Cancer Inst. (Bethesda), 92: 1926-1934, 2000.
10. 2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance. Clin. Cancer Res., 5: 251-256, 1999.
11. Gee, J. M. W., Willsher, P. C., Kenny, F. S., Robertson, J. F. R., Pinder, S. E., Ellis, I. O., and Nicholson, R. I. Endocrine response and resistance in breast cancer: a role for the transcription factor fos. Int. J. Cancer, 84: 54-61, 1999.
12. Paech, K., Webb, P., Kuiper, G. G., Nilsson, S., Gustafsson, J., Kushner, P. J., and Scanlan, T. S. Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites. Science (Wash. DC), 277: 1508-1510, 1997.
13. Fuqua, S. A. W., Schiff, R., Parra, I., Friedrichs, W. E., Su, J-L., McKee, D. D., Slentz-Kesler, K., Moore, L. B., Willson, T. M., and Moore, J. T. Expression of wild-type estrogen receptor β and variant isoforms in human breast cancer. Cancer Res., 59: 5425-5428, 1999.
14. Nicholson, R. I., McClelland, R. A., Robertson, J. R. F., and Gee, J. M. W. Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer. Endocr. Rel. Cancer, 6: 373-387, 1999.
15. Bunone, G., Briand, P., Miksicek, R., and Picard, D. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J., 15: 2174-2183, 1996.
16. Simoncini, T., Hafezi-Moghadam, A., Brazil, D. P., Ley, K., Chin, W. W., and Liao, J. K. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature (Lond.), 407: 538-541, 2000.
17. Lee, A. V., Jackson, J. G., Gooch, J. L., Hilsenbeck, S. G., Coronado-Heinsohn, E., Osborne, C. K., and Yee, D. Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol. Endocrinol., 13: 787-796, 1999.
18. Font de Mora, J., and Brown, M. AIB1 is a conduit for kinase-mediated growth factor signaling to estrogen receptor. Mol. Cell. Biol., 20: 5041-5047, 2000.
19. Hynes, N. E., Horsch, K., Olayioye, M. A., and Badache, A. The erbB receptor tyrosine kinase family as signal integrators. Endocr. Rel. Cancer, 8: 151-159, 2001.
20. Moasser, M., Basso, A. D., Averbuch, S. D., and Rosen, N. The tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2-driven signaling and suppresses the growth of HER-2-overexpressing tumors. Cancer Res., 61: 7184-7188, 2001.
21. Wright, C., Nicholson, S., Angus, B., Sainsbury, J. R. C., Farndon, J. R., Cairns, J., Harris, A. L., and Home, C. H. W. Relationship between c-erb-B2 protein expression and response to endocrine therapy in advanced breast cancer. Br. J. Cancer, 65: 118-121, 1992.
22. Gee, J. M. W., Robertson, J. F. R., Ellis. I. O., and Nicholson, R. I. Phosphorylation of erk 1/2 mitogen activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int. J. Cancer, 95: 247-254, 2001.
23. McClelland, R. A., Barrow, D., Madden, T-A., Dutkowski, C. M., Pamment, J., Knowlden, J. M., Gee, J. M. W., and Nicholson, R. I. Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). Endocrinology, 142: 2776-2788, 2001.
24. Jeng, M-H., Yue, W., Eischeid, A., Wang, J-P., and Santen, R. J. Role of MAP kinase in the enhanced cell proliferation of long-term estrogen deprived human breast cancer cells. Breast Cancer Res. Treat., 62: 167-175, 2000.
25. Gee, J. M., Hutcheson, I. R., Knowlden, J. M., Barrow, D., Harper, M. E., Wakeling, A. E., and Nicholson, R. I. The EGFR-selective tyrosine kinase inhibitor ZD 1839 (Iressa) is an effective inhibitor of tamoxifen-resistant breast cancer growth. Proc. Am. Soc. Clin. Oncol., 20, 71a, 2001.
26. Hutcheson, I. R., Knowlden, J. M., Barrow, D., Jones, H. E., Gee, J. M., and Nicholson, R. I. The novel ER down-regulator, Faslodex, modulates EGFR/MAPK activity in tamoxifen-resistant MCF-7 breast cancer cells. Clin. Cancer Res., 7, 3778s, 2001.
27. Chan, C. M. W., Lykkesfeldt, A. E., and Johnston, S. R. D. Change in ligand-dependent growth and ERE/AP-1 gene transcription in endocrine resistant breast cancer. Proc. Am. Assoc. Cancer Res., 42, 240, 2001.
28. Martin, L-A., Chan, C. M. W., Marshall, C., and Dowsett, M. The involvement of the MAPK signalling pathway in the adaptation of MCF-7 cells to long-term oestrogen deprivation. Breast Cancer Res., 2, S26, 2000.
29. Massarweh, S., Shou, J., Mohsin, S. K., Ge, M., Wakeling, A. E., Osborne, C. K., and Schiff, R. Inhibition of epidermal growth factor/HER2 receptor signaling using ZD1839 (Iressa) restores tamoxifen sensitivity and delays resistance to estrogen deprivation in HER2-overexpressing breast tumors. Proc. Am. Soc. Clin. Oncol., 21, 33a, 2002.
30. Kurokawa, H., Lenferink, A. E. G., Simpson, J. F., Pisacane, P. I., Sliwkowski, M. X., Forbes, J. T., and Arteaga, C. L. Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res., 60: 5887-5894, 2000.
31. Keshamouni, V. G., Mattingly, R. R., and Reddy, K. B. Mechanism of 17-β estradiol-induced Erk 1/2 activation in breast cancer cells. J. Biol. Chem., 277: 22558-22565, 2002.
32. Nicholson, R. I., Harper, M. E., Hutcheson, I. R., Madden, T. A., Barrow, D., Knowlden, J. M., Jordan, N., Wakeling, A. E., and Gee, J. M. ZD1839 (Iressa) improves the antitumor activity of tamoxifen in anti-hormone-responsive breast cancer cells. Clin. Cancer Res., 7, 3766s, 2001.
33. End, D. W., Smets, G., Todd, A. V., Applegate, T. L., Fuery, C. J., Angibaud, P., Venet, M., Sanz, G., Poignet, H., Skrzat, S., Devine, A., Wouters, W., and Bowden, C. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res., 61: 131-137, 2001.
34. Kelland, L. R., Smith, V., Valenti, M., Patterson, L., Clarke, P. A., Detre, S., End, D. W., Howes, A. J., Dowsett, M., Workman, P., and Johnston, S. R. D. Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer. Clin. Cancer Res., 7: 3544-3550, 2001.
35. Lee, F. Y. F., Arico, M., Camuso, A., Clark, J. L., Fager, K., Inigo, I., Giardiniere, M., Kan, D., Kennedy, K., Manne, V., et al. The FT inhibitor BMS-214662 selectively targets the non-proliferating cell subpopulation in solid tumors: implications for a synergistic therapeutic strategy. Proc. Am. Assoc. Cancer Res., 42, 260, 2001.
36. Du, W., Liu, A., and Prendergast, G. C. Activation of the P13′KAKT pathway masks the pro-apoptotic effects of farnesyltransferase inhibitors. Cancer Res., 59: 4208-4212, 1999.
37. Ranson, M., Hammond, L. A., Ferry, D., Kris, M., Tullo, A., Murray, P. I., Mill, M., Averbuch, S., Ochs, J., Morris, C., et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid malignant tumours: results of a Phase I trial. J. Clin. Oncol., 20: 2240-2250, 2002.
38. Kris, M. G., Natale, R. B., Herbst, R. S., Lynch, T. J., Prager, D., Belani, C. P., Schiller, J. H., Kelly, K., Spiridonidis, C., Albain, K. S., et al. A Phase II trial of ZD1839 (Iressa) in advanced non-small cell lung cancer patients who had failed platinum and docetaxel regimens (IDEAL 2). Proc. Am. Soc. Clin. Oncol., 21: 292a, 2002.
39. Ciardiello, F., Caputo, R., Bianco, R., Damianco, V., Pomatico, G., De Placido, S., Bianco, A. R., and Tortora, G. Antitumor effect and potentiation of cytoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor selective tyrosine kinase inhibitor. Clin. Cancer Res., 6: 2053-2063, 2000.
40. Moulder, S. L., Yakes, F. M., Muthuswamy, S. K., Bianco, R., Simpson, J. F., and Arteaga, C. L. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res., 61: 8887-8895, 2001.
41. Chan, K. C., Knox, W. F., Gee, J. M. W., Morris, J. M., Nicholson, R. I., Potten, C. S., and Bundred, N. J. Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breast. Cancer Res., 62: 122-128, 2002.
42. Hidalgo, M., Siu, L. L., Nemunaitas, J., Rizzo, J., Hammond, L. A., Takimoto, C., Eckhardht, S. G., Tolcher, A., Britten, C. D., Denis, L., Ferrante, K., Von Hoff, D. D., Silberman, S., and Rowinsky, E. C. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J. Clin. Oncol., 19: 3267-3279, 2001.
43. Perez-Soler, R., Chachoua, A., Huberman, M., Karp, D., Rigas, J., Hammond, L., Rowinsky, E., Preston, G., Ferrante, K. J., Allen, L. F., et al. A Phase II trial of the epidermal growth factor receptor tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients with advanced EGFR expressing non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol., 20: 310a, 2001.
44. Senzer, N. N., Soulieres, D., Siu, L., Agarwala, S., Vokes, E., Hidalgo, M., Silberman, S., Allen, L., Ferrante, K., Fisher, D., et al. Phase II evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with adavanced squamous cell carcinoma of the head and neck. Proc. Am. Soc. Clin. Oncol., 20: 2a, 2001.
45. Traxler, P., Buchdunger, E., Furet, P., Gschwind, H-P., Ho, P., Mett, H., O'Reilly, T., and Thomas, H. Pre-clinical profile of PKI-166: a novel and potent EGFR tyrosine kinase inhibitor for clinical development. Clin. Cancer Res., 5: 3750s, 1999.
46. Brandt, R., Wong, A. M-L., and Hynes, N. E. Mammary glands reconstituted with neu/erbB2 transformed HC11 cells provide a novel orthotopic tumor model for testing anti-cancer agents. Oncogene, 20: 5459-5465, 2001.
47. Murren, J. R., Papadimitrakopoulou, V. A., Sizer, K. C., Vaidyanathan, S., Ravera, C., and Abbruzzese, J. L. A Phase I dose-escalating study to evaluate the biological activity and pharmacokinetics of PKI-166, a novel tyrosine kinase inhibitor, in patients with advanced cancer. Proc. Am. Soc. Clin. Oncol., 21: 95a, 2002.
48. DeSimone, P. A., Bence, A. K., Anderson, E. B., Halepota, M. A., Smith, D. A., Koch, K. M., Stead, A. G., Mangum, S. G., Spector, N. L., Davis, G. A., et al. A Phase I study to investigate the safety, tolerability and pharmacokinetics of single oral escalating doses of GW572016 in healthy volunteers. Proc. Am. Soc. Clin. Oncol., 21: 94a, 2002.
49. Fry, D. W. Site-directed irreversible inhibitors of the erbB family of receptor tyrosine kinase as novel chemotherapeutic agents for cancer. Anti-Cancer Drug Design, 15: 3-16, 2000.
50. Rinehart, J. J., Wilding, G., Willson, J., Krishnamurthi, S., Natale, R., Mani, S., Burnett, D., Olson, S., Bycott, P., Owens-Grillo, J. K., et al. A Phase I clinical and pharmacokinetic study of oral CI-1033, a pan-erbB tyrosine kinase inhibitor, in patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol., 21: 11a, 2002.
51. Zinner, R. G., Donato, N., Nemunaitas, J., Cunningham, C., Shin, H. J., Zheng, P. S., Zentgraf, R. E., Ayers, G. D., Glisson, B. S., Khuri, F. R., Kies, M. S., et al. Biomarker modulation in tumor and skin biopsy samples from patients with solid tumors following treatment with the pan-erbB tyrosine kinase inhibitor CI-1033. Proc. Am. Soc. Clin. Oncol., 21: 15a, 2002.
52. Clark, G. J., and Der, C. J. Aberrant function of the Ras signal transduction pathway in human breast cancer. Breast Cancer Res. Treat., 35: 133-144, 1995.
53. Johnston, S. R. D. Famesyl transferase inhibitors: a novel targeted therapy for cancer. Lancet Oncol., 2: 18-26, 2001.
54. Liu, M., Bryant, M. S., Chen, J., Lee, S., Yaremko, B., Lipari, P., Malkowski, M., Ferrari, E., Nielsen, L., Prioli, N., Dell, J., Sinha, D., Syed, J., Korfmacher, W. A., Nomeir, A. A., Lin, C-C., Wamg, L., Taveras, A. G., Doll, R. J., Ngoroge, F. G., Mallams, A. K., Remiszewski, S., Catino, J., Girijavallabhan, V. M., Kirschmeier, P., and Bishop, W. R. Anti-tumor activity of SCH66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice. Cancer Res., 58: 4947-4956, 1998.
55. Eskens, F., Awada, A., Cutler, D. L., deJonge, M. J. A., Luyten, G. P. M., Faber, M. N., Statkevich, P., Sparreboom, A., Verweij, J., Hanauske, A., and Piccart, M. Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily in patients with advanced solid tumors. J. Clin. Oncol., 19: 1167-1175, 2001.
56. Adjei, A. A., Erlichman, C., Davis, J. D., Cutler, D. L., Sloan, J. A., Marks, R. S., Hanson, L. J., Svingen, P. A., Atherton, P., Bishop, R., Kirschmeier, P., and Kaufmann, S. H. A Phase I trial of the farnesyl transferase inhibitor SCH66336; evidence for biological and clinical activity. Cancer Res., 60: 1871-1877, 2000.
57. Hudes, G. R., Schol, J., Baab, J., Rogatko, A., Bol, C., Horak, I., Langer, C., Goldstein, L. J., Szarka, C., Meropol, N. J., and Weiner, L., Phase I clinical and pharmacokinetic trial of the farnesylytransferase inhibitor R115777 on a 21-day dosing schedule. Proc. Am. Soc. Clin. Oncol., 18: A601, 1999.
58. Crul, M., de Klerk, G. J., Swart, M., van't Veer, L. J., de Jong, D., Boerrigter, L., Palmer, P. A., Bol, C. J., Tan, H., de Gast, G. C., Beijnen, J. H., and Schellens, J. H. M. Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer. J. Clin. Oncol., 20: 2726-2735, 2002.
59. Johnston, S. R. D., Hickish, T., Houston, S., Ellis, P. A., Howes, A. J., and Thibault, A. Efficicay and tolerability of two dosing regimens of R115777 (Zarnestra), a farnesyl protein transferase inhibitor, in patients with advanced breast cancer. Proc. Am. Soc. Clin. Oncol., 21: 35a, 2002.
60. Lyons, J. F., Wilhelm, S., Hibner, B., and Bollag, G. Discovery of a novel Raf kinase inhibitor. Endocr. Rel. Cancer, 8: 219-225, 2001.
61. Awada, A., Hendlisz, A., Gil, T., Bleiberg, H., Bartholomoeus, S., De Valerioal, D., DeWitte, M., and Piccart, M. A clinical, pharmacokinetic and pharmacodynamic Phase I study of the raf kinase inhibitor BAY 43-9006 in patients with advanced solid tumours. Clin. Cancer Res., 7, 3768s, 2001.
62. Senderowicz, A. M., and Sausville, E. A. Preclinical and clinical development of cyclin-dependent kinase modulators. J. Natl. Cancer Inst. (Bethesda), 92: 376-387, 2000.
63. Yu, K., Toral-Barza, L., Discafani, C., Zhang, W-G., Skotnicki, J., Frost, P., and Gibbons, J. J. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr. Rel. Cancer, 8: 249-258, 2001.
64. Chan, S., Johnston, S. R. D., Scheulen, M. E., Mross, K., Morant, R., Lahr, A., Feussner, A., Berger, M., and Kirsch, T. A Phase II study of the safety and tolerability of CCI-779 for patients with locally advanced or metastatic breast cancer failing prior chemotherapy. Proc. Am. Soc. Clin. Oncol., 21: 44a, 2002.